DK2831111T3 - Ang2-bindende molekyler - Google Patents

Ang2-bindende molekyler Download PDF

Info

Publication number
DK2831111T3
DK2831111T3 DK13718796.9T DK13718796T DK2831111T3 DK 2831111 T3 DK2831111 T3 DK 2831111T3 DK 13718796 T DK13718796 T DK 13718796T DK 2831111 T3 DK2831111 T3 DK 2831111T3
Authority
DK
Denmark
Prior art keywords
gly
ser
ala
val
tyr
Prior art date
Application number
DK13718796.9T
Other languages
English (en)
Inventor
Eric Borges
Andreas Gschwind
Rene Georg Ott
Marie-Ange Buyse
Joachim Boucneau
Pascal Merchiers
Erik Depla
Frederik Stevenaert
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48190468&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2831111(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Application granted granted Critical
Publication of DK2831111T3 publication Critical patent/DK2831111T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3038—Kidney, bladder
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Claims (15)

1. Ang2-bindende molekyle omfattende et enkelt variabelt immunoglobulindomæne, hvor det det enkelte variable immunoglobulindomæne omfatter tre komplementaritetsbestemmende regioner CDR1, CDR2 og CDR3, hvor CDR1 har en aminosyresekvens vist i SEQ ID NO: 168, CDR2 har en aminosyresekvens vist i SEQ ID NO: 171, og CDR3 har en aminosyresekvens vist i SEQ ID NO: 175.
2. Ang2-bindende molekyle ifølge krav 1, hvor det enkelte variable immunoglobulindomæne er et VHH.
3. Ang2-bindende molekyle ifølge krav 2, hvor nævnte VHH består af et enkelt variabelt immunoglobulindomæne med en sekvens bestående af SEQ ID NO: 166.
4. Ang2-bindende molekyle ifølge et hvilket som helst af kravene 1 til 3, hvor nævnte VHH eller nævnte enkelte variable immunoglobulindomæne har en modifikation eller udskiftning på sin N-terminale ende, hvor modifikationen er en deletering af den første aminosyre, og udskiftningen er en erstatning af den første aminosyre med en anden aminosyre.
5. Nukleinsyremolekyle kodende for det Ang2-bindende molekyle ifølge et hvilket som helst af kravene 1 til 4.
6. Ekspressionsvektor omfattende nukleinsyremolekylet ifølge krav 5.
7. Værtscelle, der bærer en eller flere ekspressionsvektorer ifølge krav 6.
8. Fremgangsmåde til fremstilling af det Ang2-bindende molekyle ifølge et hvilket som helst af kravene 1 til 4, hvilken fremgangsmåde omfatter følgende trin: at transficere en værtscelle med en eller flere af ekspressionsvektorerne ifølge krav 6, at dyrke værtscellen og at isolere og oprense det Ang2-bindende molekyle.
9. Farmaceutisk sammensætning omfattende som virksom bestanddel et eller flere af de nævnte Ang2-bindende molekyler ifølge et hvilket som helst af kravene 1 til 4 og mindst et fysiologisk acceptabelt bærestof.
10. Farmaceutisk sammensætning ifølge krav 9, yderligere omfattende et eller flere yderligere terapeutiske midler.
11. Farmaceutisk sammensætning ifølge et hvilket som helst af kravene 9 eller 10 til anvendelse i behandling af en sygdom, som er forbundet med Ang2-formidlede virkninger på angiogenesen.
12. Farmaceutisk sammensætning ifølge krav 11 til anvendelse i behandling af cancer og cancersygdomme.
13. Farmaceutisk sammensætning ifølge krav 11 til anvendelse i behandling af øjensygdomme.
14. Farmaceutisk sammensætning ifølge krav 13, hvor øjensygdommen er aldersbetinget makuladegeneration eller diabetisk retinopati.
15. Farmaceutisk sammensætning ifølge krav 11 til anvendelse i behandling af kroniske nyresygdomme.
DK13718796.9T 2012-03-30 2013-03-27 Ang2-bindende molekyler DK2831111T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12162615 2012-03-30
PCT/EP2013/056635 WO2013144266A1 (en) 2012-03-30 2013-03-27 Ang2-binding molecules

Publications (1)

Publication Number Publication Date
DK2831111T3 true DK2831111T3 (da) 2019-04-29

Family

ID=48190468

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13718796.9T DK2831111T3 (da) 2012-03-30 2013-03-27 Ang2-bindende molekyler

Country Status (27)

Country Link
US (5) US20130259859A1 (da)
EP (1) EP2831111B1 (da)
JP (1) JP5970734B2 (da)
KR (1) KR102020255B1 (da)
CN (1) CN104321344B (da)
AU (1) AU2013241769B2 (da)
BR (1) BR112014023415B1 (da)
CA (1) CA2865464C (da)
CL (1) CL2014002393A1 (da)
CY (1) CY1122007T1 (da)
DK (1) DK2831111T3 (da)
EA (1) EA031182B1 (da)
ES (1) ES2729165T3 (da)
HR (1) HRP20190817T1 (da)
HU (1) HUE044263T2 (da)
IL (1) IL234234B (da)
IN (1) IN2014DN06904A (da)
LT (1) LT2831111T (da)
MX (1) MX350248B (da)
NZ (1) NZ628584A (da)
PH (1) PH12014502179B1 (da)
PL (1) PL2831111T3 (da)
PT (1) PT2831111T (da)
RS (1) RS58732B1 (da)
SI (1) SI2831111T1 (da)
TR (1) TR201908638T4 (da)
WO (1) WO2013144266A1 (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
WO2016057367A1 (en) 2014-10-06 2016-04-14 Dana-Farber Cancer Institute, Inc. Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
CA2964470A1 (en) 2014-10-17 2016-04-21 Amgen Inc. Antibodies directed to angiopoietin-1 and angiopoietin-2 for ocular therapies
WO2016156466A1 (en) * 2015-03-31 2016-10-06 Vhsquared Limited Peptide construct having a protease-cleavable linker
RU2749674C2 (ru) * 2015-07-29 2021-06-16 Аллерган, Инк. Антитела против ang-2, содержащие только тяжелую цепь
AU2017343779A1 (en) * 2016-10-13 2019-04-04 Dana-Farber Cancer Institute, Inc. Compositions and methods for predicting response and resistance to CTLA4 blockade in melanoma using a gene expression signature
KR102143132B1 (ko) * 2016-12-26 2020-08-10 기초과학연구원 항 Ang2 항체를 포함하는 안구질환 예방 및 치료용 조성물
EP3565839A4 (en) 2017-01-05 2021-04-21 Gensun Biopharma Inc. CHECKPOINT REGULATOR ANTAGONISTS
BR112019022074A2 (pt) * 2017-06-02 2020-05-12 Boehringer Ingelheim International Gmbh Terapia de combinação anticâncer
CN108659130B (zh) * 2018-05-28 2021-09-10 长春力太生物技术有限公司 一种抗癌胚抗原纳米抗体及其应用
KR20210028222A (ko) 2018-06-29 2021-03-11 젠선 바이오파마, 인코포레이티드 항종양 면역 체크포인트 조절 길항제
CN113728004A (zh) * 2019-02-25 2021-11-30 药物抗体公司 抗Ang2抗体及其用途
US20220185875A1 (en) * 2019-03-18 2022-06-16 Jiangsu Hengrui Medicine Co., Ltd. Bispecific antibody specifically bound to vegf and ang2
EP3990116A1 (en) 2019-06-28 2022-05-04 Gensun Biopharma Inc. ANTITUMOR ANTAGONIST CONSISTING OF A MUTATED TGFß1 - RII EXTRACELLULAR DOMAIN AND AN IMMUNOGLOBULIN SCAFFOLD
CN111875706B (zh) * 2020-07-16 2021-03-30 广州康盛生物科技股份有限公司 一种抗人IgE蛋白的单域抗体及其应用
US20220389120A1 (en) 2021-06-03 2022-12-08 Gensun Biopharma Inc. Multispecific antagonists
CA3231417A1 (en) * 2021-09-10 2023-03-16 Jian Shi Anti-ang2 antibody, preparation method therefor, and application thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994004678A1 (en) 1992-08-21 1994-03-03 Casterman Cecile Immunoglobulins devoid of light chains
US5643755A (en) 1994-10-07 1997-07-01 Regeneron Pharmaceuticals Inc. Nucleic acid encoding tie-2 ligand
US5814464A (en) 1994-10-07 1998-09-29 Regeneron Pharma Nucleic acids encoding TIE-2 ligand-2
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
CA2433877C (en) 2001-01-17 2014-11-18 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
DK1399484T3 (da) 2001-06-28 2010-11-08 Domantis Ltd Dobbelt-specifik ligand og anvendelse af denne
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US7205275B2 (en) 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
WO2004041865A2 (en) 2002-11-08 2004-05-21 Ablynx N.V. Stabilized single domain antibodies
AU2003286004A1 (en) 2002-11-08 2004-06-07 Ablynx N.V. Single domain antibodies directed against interferon- gamma and uses therefor
EP2251357A1 (en) 2003-11-07 2010-11-17 Ablynx N.V. Camelidae single domain antibodies VHH directed against epidermal growth factor receptor and uses therefor
US20050284249A1 (en) 2004-06-29 2005-12-29 Arnone David F Worm type gear mover assembly
CA2583017A1 (en) 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti-amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenerative neural diseases such as alzheimer's disease
CN105085678B (zh) 2004-12-21 2019-05-07 阿斯利康公司 血管生成素-2的抗体及其应用
EP2365000A3 (en) 2005-05-18 2013-01-16 Ablynx N.V. Improved nanobodiesTM against tumor necrosis factor-alpha
WO2007143689A2 (en) 2006-06-06 2007-12-13 Genentech, Inc. Compositions and methods for modulating vascular development
AU2007285695B2 (en) 2006-08-18 2012-05-24 Ablynx N.V. Amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signalling
AU2008219216A1 (en) 2007-02-21 2008-08-28 Ablynx N.V. Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization
DE112009000507T5 (de) 2008-03-05 2011-02-10 Ablynx Nv Neue Antigen-bindende Dimerkomplexe, Verfahren zu ihrer Herstellung und ihre Verwendung
ES2713864T3 (es) * 2008-06-05 2019-05-24 Ablynx Nv Secuencias de aminoácidos dirigidas contra proteínas de la envuelta de un virus y polipéptidos que comprenden las mismas para el tratamiento de enfermedades virales
AU2009324354B2 (en) * 2008-12-10 2016-04-14 Ablynx Nv Amino acid sequences directed against the Angiopoietin/Tie system and polypeptides comprising the same for the treatment of diseases and disorders related to angiogenesis
JO3182B1 (ar) * 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
US20130078247A1 (en) * 2011-04-01 2013-03-28 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to dii4 and ang2
US9527925B2 (en) * 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2

Also Published As

Publication number Publication date
EA031182B1 (ru) 2018-11-30
RS58732B1 (sr) 2019-06-28
CL2014002393A1 (es) 2015-01-23
US20200207845A1 (en) 2020-07-02
KR20140146606A (ko) 2014-12-26
ES2729165T3 (es) 2019-10-30
NZ628584A (en) 2016-04-29
EP2831111A1 (en) 2015-02-04
CA2865464C (en) 2022-07-12
EP2831111B1 (en) 2019-03-20
HRP20190817T1 (hr) 2019-06-28
SI2831111T1 (sl) 2019-06-28
JP5970734B2 (ja) 2016-08-17
IN2014DN06904A (da) 2015-05-15
AU2013241769B2 (en) 2017-05-11
CY1122007T1 (el) 2020-10-14
CN104321344B (zh) 2017-11-21
PH12014502179A1 (en) 2014-12-10
PH12014502179B1 (en) 2014-12-10
US20230203146A1 (en) 2023-06-29
BR112014023415B1 (pt) 2022-04-12
BR112014023415A2 (pt) 2017-07-11
IL234234B (en) 2020-06-30
HUE044263T2 (hu) 2019-10-28
CN104321344A (zh) 2015-01-28
US20190135907A1 (en) 2019-05-09
PL2831111T3 (pl) 2019-09-30
US20170107281A1 (en) 2017-04-20
AU2013241769A1 (en) 2014-08-28
PT2831111T (pt) 2019-05-31
MX350248B (es) 2017-08-31
MX2014011171A (es) 2015-03-06
KR102020255B1 (ko) 2019-09-10
TR201908638T4 (tr) 2019-07-22
US20130259859A1 (en) 2013-10-03
EA201401065A1 (ru) 2015-03-31
JP2015516805A (ja) 2015-06-18
CA2865464A1 (en) 2013-10-03
LT2831111T (lt) 2019-05-10
WO2013144266A1 (en) 2013-10-03

Similar Documents

Publication Publication Date Title
US20230203146A1 (en) Ang2-binding molecules
US20220363744A1 (en) Vegf-binding molecules
CA2827817C (en) Bispecific binding molecules binding to vegf and ang2
US20140120095A1 (en) Bispecific binding molecules for anti-angiogenesis therapy
KR20120115217A (ko) Ｄｌｌ４－결합 분자
TWI535735B (zh) 結合ｄｌｌ４及ａｎｇ２之雙特異性結合分子
OA16772A (en) Bispecific binding molecules binding to DII4 and Ang2.